Smith Graham & Co Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Smith Graham & Co Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$5.94M	Buy	83,121 +21,272	+34%	+$1.26M	0.68%	61
2023 Q3	$3.71M	Sell	61,849 -587	-0.9%	-$38.6K	0.46%	109
2023 Q2	$4.5M	Sell	62,436 -2,727	-4%	-$205K	0.54%	87
2023 Q1	$4.79M	Sell	65,163 -209	-0.3%	-$14.9K	0.58%	80
2022 Q4	$4.37M	Sell	65,372 -72,257	-53%	-$4.7M	0.53%	90
2022 Q3	$7.39M	Sell	137,629 -189	-0.1%	-$11.1K	0.98%	27
2022 Q2	$7.67M	Sell	137,818 -1,377	-1%	-$78.1K	0.95%	32
2022 Q1	$9.77M	Sell	139,195 -894	-0.6%	-$64.9K	1.01%	24
2021 Q4	$13.5M	Sell	140,089 -11,303	-7%	-$1.04M	1.34%	9
2021 Q3	$13.2M	Sell	151,392 -6,324	-4%	-$489K	1.32%	12
2021 Q2	$12.9M	Sell	157,716 -5,628	-3%	-$468K	1.14%	18
2021 Q1	$15.5M	Buy	163,344 +6,984	+4%	+$660K	1.26%	13
2020 Q4	$9.7M	Buy	156,360 +38,172	+32%	+$2.18M	0.89%	34
2020 Q3	$7.03M	Buy	+118,188	New	+$8.06M	0.8%	46

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smith Graham & Co Investment Advisors's LGND Position: Q4 2023 in Review

Smith Graham & Co Investment Advisors increased its Ligand Pharmaceuticals (LGND) stake by 34% in Q4 2023, buying an estimated $1.26M and bringing the position to 83,121 shares worth $5.94M. The position accounts for 0.68% of the portfolio, ranked #61.

Smith Graham & Co Investment Advisors first reported a position in LGND in Q3 2020 and has held it in 14 quarters since. The position peaked at $15.5M in Q1 2021. 211 funds tracked by Wall St. Rank hold LGND as of Q4 2023.

Smith Graham & Co Investment Advisors held 83,121 shares of Ligand Pharmaceuticals worth $5.94M as of Q4 2023.
Smith Graham & Co Investment Advisors bought 21,272 Ligand Pharmaceuticals shares in Q4 2023, an estimated $1.26M.
Ligand Pharmaceuticals made up 0.68% of Smith Graham & Co Investment Advisors's portfolio in Q4 2023, its #61 holding.
Smith Graham & Co Investment Advisors first reported a position in Ligand Pharmaceuticals in Q3 2020 and has held it in 14 quarters since.
Smith Graham & Co Investment Advisors's Ligand Pharmaceuticals position peaked at $15.5M in Q1 2021.
211 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2023.

Based on Smith Graham & Co Investment Advisors's 13F filing for Q4 2023, filed 29 Jan 2024.